The Unfinished Science of Boxed Drug Warnings - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Incomplete Understanding of Boxed Warnings for Medications

  • By

  • John G. Rizk

  • John C. Lewin

  • May 22, 2026

Share

Clinical Scorecard: The Incomplete Understanding of Boxed Warnings for Medications

At a Glance

CategoryDetail
Condition
Key MechanismsBoxed warnings as a serious safety alert mechanism by the FDA
Target Population
Care Setting

Key Highlights

  • 30% relative reduction in montelukast initiation after the boxed warning
  • Boxed warnings are the FDA's most serious safety alert
  • Montelukast's boxed warning is drug-specific, not class-wide

Guideline-Based Recommendations

Diagnosis

    Management

    • Reserve montelukast for patients with refractory symptoms or those who do not improve with other therapies

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with asthma and allergic rhinitis

        Prescribing behavior may be influenced by perceived risks and benefits

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          The Unfinished Science of Boxed Drug Warnings

          • by John G. Rizk, John C. Lewin

          • May 22, 2026

          Related Content

          Immunization Awareness Month: How RTs Help Protect Patients

          Can Tezepelumab Reduce Steroid Dependence?

          Phase 3 SUNRISE trial evaluates whether patients with severe asthma can taper maintenance oral corticosteroids while maintaining asthma control.

          FDA Expands Afrezza to Pediatric Diabetes

          The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.